Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Toray Industries, Inc
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Compugen Ltd
Eli Lilly and Company
Astellas Pharma Inc
Fate Therapeutics
Memorial Sloan Kettering Cancer Center
Five Prime Therapeutics, Inc.
AbbVie